Switch theme
Sign up to access all valuation multiples
GlaxoSmithKline Pharmaceuticals Ltd is an India-based subsidiary of GlaxoSmithKline plc. GSK India develops and manufactures medicines, vaccines, and consumer products. Its medicines portfolio includes prescription drugs for conditions that include asthma, infectious diseases, mental health, and digestion, as well as nonprescription nutrition and cosmetic products. Its vaccines product line includes treatments for conditions such as influenza, HPV, hepatitis, and measles. Its consumer healthcare products include Horlicks-brand packaged food and beverage powders among other retail products. The company derives majority of its revenue from India.
1924
3.2K+
LTM Revenue $446M
LTM EBITDA $140M
$6.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
GSK India has a last 12-month revenue (LTM) of $446M and a last 12-month EBITDA of $140M.
In the most recent fiscal year, GSK India achieved revenue of $439M and an EBITDA of $156M.
GSK India expects next 12-month revenue of XXX and NTM EBITDA of XXX
See GSK India valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $446M | XXX | $439M | XXX | XXX | XXX |
| Gross Profit | $446M | XXX | $276M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 63% | XXX | XXX | XXX |
| EBITDA | $140M | XXX | $156M | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 35% | XXX | XXX | XXX |
| EBIT | $137M | XXX | $130M | XXX | XXX | XXX |
| EBIT Margin | 31% | XXX | 30% | XXX | XXX | XXX |
| Net Profit | $110M | XXX | $109M | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, GSK India's stock price is INR 3295 (or $39).
GSK India has current market cap of INR 558B (or $6.5B), and EV of INR 532B (or $6.2B).
See GSK India trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.2B | $6.5B | XXX | XXX | XXX | XXX | $0.65 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, GSK India has market cap of $6.5B and EV of $6.2B.
GSK India's trades at 14.5x EV/Revenue multiple, and 43.7x EV/EBITDA.
Equity research analysts estimate GSK India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GSK India has a P/E ratio of 59.4x.
See valuation multiples for GSK India and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.5B | XXX | $6.5B | XXX | XXX | XXX |
| EV (current) | $6.2B | XXX | $6.2B | XXX | XXX | XXX |
| EV/Revenue | 14.0x | XXX | 14.5x | XXX | XXX | XXX |
| EV/EBITDA | 44.7x | XXX | 43.7x | XXX | XXX | XXX |
| EV/EBIT | 45.4x | XXX | 51.1x | XXX | XXX | XXX |
| EV/Gross Profit | 14.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 59.4x | XXX | 66.2x | XXX | XXX | XXX |
| EV/FCF | 42.8x | XXX | 49.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGSK India's last 12 month revenue growth is 10%
GSK India's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $46K for the same period.
GSK India's rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GSK India's rule of X is 56% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for GSK India and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | 43% | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 56% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $46K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GSK India acquired XXX companies to date.
Last acquisition by GSK India was XXXXXXXX, XXXXX XXXXX XXXXXX . GSK India acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was GSK India founded? | GSK India was founded in 1924. |
| Where is GSK India headquartered? | GSK India is headquartered in India. |
| How many employees does GSK India have? | As of today, GSK India has 3.2K+ employees. |
| Is GSK India publicy listed? | Yes, GSK India is a public company listed on BOM. |
| What is the stock symbol of GSK India? | GSK India trades under 500660 ticker. |
| When did GSK India go public? | GSK India went public in 1991. |
| Who are competitors of GSK India? | Similar companies to GSK India include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of GSK India? | GSK India's current market cap is $6.5B |
| What is the current revenue of GSK India? | GSK India's last 12 months revenue is $446M. |
| What is the current revenue growth of GSK India? | GSK India revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of GSK India? | Current revenue multiple of GSK India is 14.0x. |
| Is GSK India profitable? | Yes, GSK India is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of GSK India? | GSK India's last 12 months EBITDA is $140M. |
| What is GSK India's EBITDA margin? | GSK India's last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of GSK India? | Current EBITDA multiple of GSK India is 44.7x. |
| What is the current FCF of GSK India? | GSK India's last 12 months FCF is $146M. |
| What is GSK India's FCF margin? | GSK India's last 12 months FCF margin is 33%. |
| What is the current EV/FCF multiple of GSK India? | Current FCF multiple of GSK India is 42.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
